Illumina Announces Favorable Outcome of Its Patent Litigation Against Life Technologies, Inc.

  Illumina Announces Favorable Outcome of Its Patent Litigation Against Life
  Technologies, Inc.

Business Wire

SAN DIEGO -- March 21, 2013

Illumina, Inc. (NASDAQ: ILMN) announced today that District Court Judge Cathy
Ann Bencivengo of the U.S. District Court for the Southern District of
California granted Illumina’s motion for summary judgment that its sequencing
systems do not infringe U.S. Patent Nos. 5,616,478; 5,958,698 and 6,001,568,
being asserted by Life Technologies Corporation in a lawsuit filed against
Illumina in 2009. The Court ruled that, “Life Tech cannot establish, as a
matter of law, that the accused Illumina systems infringe” the patents.

Jay Flatley, Illumina’s President and CEO, stated, “We are obviously very
pleased with the favorable outcome of this suit. Since Life Technologies filed
this patent infringement suit against Illumina in 2009, we have consistently
believed and strongly argued that our sequencing technology does not infringe
any of the patents Life Technologies asserted against us in this case. The
federal court’s ruling has now vindicated our position. While our policy is to
respect the valid and enforceable intellectual property rights of others, and
take licenses where appropriate, this case demonstrates we are determined to
defend vigorously any unfounded claims of infringement.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
Investor Relations
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
Public Relations
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.